Using artificial intelligence to find new drugs faster

Peptides are the hottest area of new drug development. Medications derived from these "short" naturally occurringproteins – a midpoint between small molecules and large antibodies -- are highly targeted and often much less toxic than other treatments. It's no wonder, then, that peptide-derived drugs have become a $20 billion market, expected to grow to $43 billion by 2024, according to Zion Market Research. Insulin is probably the most famous peptide drug. Newer peptide-derived medicines like Victoza and Byetta also treat diabetes; Zoladex, Lupron and Sandostatin are used to fight cancer.